Free Trial
NASDAQ:ATAI

Atai Life Sciences Q1 2024 Earnings Report

Atai Life Sciences logo
$2.24 -0.09 (-3.66%)
As of 01:02 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Atai Life Sciences EPS Results

Actual EPS
-$0.17
Consensus EPS
-$0.20
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Atai Life Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Atai Life Sciences Announcement Details

Quarter
Q1 2024
Time
Before Market Opens
Conference Call Date
Wednesday, May 15, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Atai Life Sciences' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Friday, August 15, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Atai Life Sciences Earnings Headlines

Elon Set to Shock the World on June 1st?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.
See More Atai Life Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atai Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atai Life Sciences and other key companies, straight to your email.

About Atai Life Sciences

Atai Life Sciences (NASDAQ:ATAI) N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

View Atai Life Sciences Profile

More Earnings Resources from MarketBeat